• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • WORLD EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • WORLD EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    FierceBiotech to Host R&D Challenges: A UK Perspective

    Chelsea Pratt
    Oct. 23, 2016 04:00PM PST
    Biotech Investing
    Biotech Investing

    On October 27, 2016, biotech experts and industry professionals will converge on London to discuss the sector’s outlook.

    On October 27, 2016, biotech experts and industry professionals will converge on London. Their purpose? To discuss R&D challenges from a UK perspective, as well as consider how the biotech sector might respond to Brexit.
    FierceBiotech is hosting the event, which takes place at the Royal Society of Medicine. The conference consists of two panels and a fireside chat, where topics up for debate will include the role of NICE in drug pricing, current industry trends and the anticipated impact of Brexit on Britain’s biotech sector.
    What is England’s influence on drug-pricing worldwide?
    How can the country attract biotech investment post-Brexit?
    Why is the clinical trial process changing … and what might it look like in the future?
    These questions, and others like them, will be considered by an esteemed group of industry experts. Speakers and panelists include Joanne Hulbert, a director of global regulatory affairs at PRA Health Sciences; Divya Chadha Manek, the Head of Commercial Business Development at the NIHR Clinical Research Network; and Dr. Jonathan Flelden, Director of Specialized Commissioning and Deputy Nation Medical Director at NHS England.
    Register now for the event. But if you’re not lucky enough to attend? Never fear. We’ll be live tweeting the conference, so stay tuned to @INN_LifeScience for real-time updates.
    And make sure to check back here following the event—you can bet we’ll be covering all of the major takeaways in detail!
    Don’t forget to follow us @INN_LifeScience for conference updates.
    Securities Disclosure: I, Chelsea Pratt, hold no direct investment interest in any company mentioned in this article.

    divya chadha-manekdrug pricingbusiness developmentchelsea pratt
    The Conversation (0)

    Go Deeper

    AI Powered
    Test tubes.

    Biotech Market Forecast: Top Trends for Biotech in 2025

    Scientist with petri dish.

    Pharma Market Forecast: Top Trends for Pharma in 2025

    Latest News

    Seegnal Inc. Announces Extension of Maccabi Health Services Contract

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×